Page last updated: 2024-11-07

propylisopropylacetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

propylisopropylacetamide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107977
CHEMBL ID238458
SCHEMBL ID1577891
MeSH IDM0053456

Synonyms (11)

Synonym
propylisopropylacetamide
2-(1-methylethyl)pentanamide
pentanamide, 2-(1-methylethyl)-
2-isopropylvaleramide
CHEMBL238458
2-isopropylpentanamide
6098-19-7
AKOS006340655
SCHEMBL1577891
DTXSID00976458
2-(propan-2-yl)pentanimidic acid

Research Excerpts

Overview

Propylisopropylacetamide is a chiral CNS-active constitutional isomer of valpromide. It is the amide derivative of the major antiepileptic drug valproic acid (VPA)

ExcerptReferenceRelevance
"Propylisopropylacetamide (PID) is a chiral CNS-active constitutional isomer of valpromide, the amide derivative of the major antiepileptic drug valproic acid (VPA). "( Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide.
Bialer, M; Devor, M; Kaufmann, D; Minert, A; Tal, M; Yagen, B, 2008
)
2.02

Pharmacokinetics

ExcerptReferenceRelevance
" MPD, the least-branched compound had the largest clearance and shortest half-life of all the amides investigated and was the least active."( Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.
Bialer, M; Haj-Yehia, A, 1989
)
0.28
"Following intravenous administration to dogs of the individual enantiomers, (R)-PID had significantly lower clearance and longer half-life than (S)-PID, however, the volumes of distribution were similar."( Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.
Bennett, GD; Bialer, M; Finnell, RH; Levy, RH; Roeder, M; Schurig, V; Spiegelstein, O; Yagen, B, 1999
)
0.3
"(R)-PID demonstrated better anticonvulsant activity, lower clearance and a longer half-life compared to (S)-PID."( Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.
Bennett, GD; Bialer, M; Finnell, RH; Levy, RH; Roeder, M; Schurig, V; Spiegelstein, O; Yagen, B, 1999
)
0.3
" administration of individual enantiomers to mice, with (R)-PID having lower clearance and longer half-life than (S)-PID."( Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents.
Bennett, GD; Bialer, M; Blotnik, S; Finnell, RH; Isoherranen, N; Spiegelstein, O; White, HS; Wilcox, KS; Woodhead, JH; Yagen, B, 2003
)
0.32
" administration of the individual enantiomers, (S)-PID had lower clearance (CL) and volume of distribution (V) and a shorter half-life (t(1/2)) than (R)-PID."( Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide.
Bialer, M; Devor, M; Kaufmann, D; Minert, A; Tal, M; Yagen, B, 2008
)
0.57

Dosage Studied

ExcerptRelevanceReference
" Dose-response effects for the induction of total cytochrome P450 ethoxyresorufin-O-deethylase (EROD) activity, and benzphetamine demethylase (BPDM) activity were studied using 10 selected tetra- to hexachlorinated PCB congeners."( Effects of polychlorinated biphenyls on cytochrome P450 induction in the chick embryo hepatocyte culture.
Robertson, LW; Rodman, LE; Shedlofsky, SI; Swim, AT, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID304102Protective index, ratio of TD50 for Sprague-Dawley rat by rotarod test to ED50 for Sprague-Dawley rat by scMET test2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid.
AID304101Protective index, ratio of TD50 for Sprague-Dawley rat by rotarod test to ED50 for Sprague-Dawley rat by MES test2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid.
AID470102Antiallodynic activity in ip dosed rat assessed as protection against spinal nerve ligation-induced neuropathic pain2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID304098Anticonvulsant activity in Sprague-Dawley rat by maximal electroshock seizure test2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid.
AID304100Neurotoxicity in Sprague-Dawley rat by rotarod test2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid.
AID304099Anticonvulsant activity in Sprague-Dawley rat by subcutaneous pentylenetetrazole test2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid.
AID470104Ratio of ED50 for antiallodynic activity in rat assessed as protection against spinal nerve ligation-induced neuropathic pain to ED50 for antiepileptic activity in rat by maximal electroshock-induced seizures assay2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID470103Antiepileptic activity in ip dosed CF1 mouse assessed as inhibition of maximal electroshock-induced seizures2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (60.87)18.7374
1990's4 (17.39)18.2507
2000's4 (17.39)29.6817
2010's1 (4.35)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.96 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]